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Gene-wide Association Study 
Reveals RNF122 Ubiquitin Ligase 
as a Novel Susceptibility Gene for 
Attention Deficit Hyperactivity 
Disorder
Iris Garcia-Martínez1,2, Cristina Sánchez-Mora1,2,3, María Soler Artigas1,2,3, Paula Rovira1,2, 
Mireia Pagerols1,2, Montse Corrales2,4, Eva Calvo-Sánchez1,2, Vanesa Richarte2,3,4, Mariona 
Bustamante5,6,7,8, Jordi Sunyer5,7,8,9, Bru Cormand  10,11,12,13, Miquel Casas1,2,3,4, Josep Antoni 
Ramos-Quiroga1,2,3,4 & Marta Ribasés  1,2,3
Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood-onset neurodevelopmental 
condition characterized by pervasive impairment of attention, hyperactivity, and/or impulsivity that 
can persist into adulthood. The aetiology of ADHD is complex and multifactorial and, despite the wealth 
of evidence for its high heritability, genetic studies have provided modest evidence for the involvement 
of specific genes and have failed to identify consistent and replicable results. Due to the lack of robust 
findings, we performed gene-wide and pathway enrichment analyses using pre-existing GWAS data 
from 607 persistent ADHD subjects and 584 controls, produced by our group. Subsequently, expression 
profiles of genes surpassing a follow-up threshold of P-value < 1e-03 in the gene-wide analyses were 
tested in peripheral blood mononucleated cells (PBMCs) of 45 medication-naive adults with ADHD and 
39 healthy unrelated controls. We found preliminary evidence for genetic association between RNF122 
and ADHD and for its overexpression in adults with ADHD. RNF122 encodes for an E3 ubiquitin ligase 
involved in the proteasome-mediated processing, trafficking, and degradation of proteins that acts 
as an essential mediator of the substrate specificity of ubiquitin ligation. Thus, our findings support 
previous data that place the ubiquitin-proteasome system as a promising candidate for its involvement 
in the aetiology of ADHD.
Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood-onset neurodevelopmental disorder 
with a high estimated prevalence of 5.3% among children and of 2.5% in adulthood1. Family and twin studies have 
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shown that genetic factors play a crucial role in ADHD susceptibility and have estimated the heritability of the 
disorder to be around 76–80% both in children and in adults1.
In spite of this high heritability, genome-wide linkage studies or hypothesis-driven candidate gene association 
analyses in ADHD have failed to identify consistent and replicable genetic factors, and provide modest evidence 
for the involvement of some specific genes on the basis of meta-analyses2–5. Aiming to overcome these issues, and 
along with advances in high-throughput technologies, a number of genome-wide association studies (GWAS) has 
been performed in ADHD in the last few years. It has been reported that around 28% of the total variance in the 
liability to ADHD may be explained by common nucleotide polymorphisms (SNPs), and that a considerable part 
of this estimated SNP-based heritability might be shared with different psychiatric disorders6, 7. GWAS in ADHD 
have shown suggestive evidence for association of cadherin 13 (CDH13) and other candidate genes, including 
monoamine system-related genes (e.g. SLC9A9 and SNAP25), the glutamate metabotropic receptor 5 (GRM5), 
the glucose-fructose oxidoreductase domain containing 1 (GFOD1), the cannabinoid receptor 1 (CNR1), the 
protein kinase CGMP-dependent 1 (PRKG1) or the nicotinic acetylcholine receptor alpha 7 (CHRNA7), among 
others2–4, 8. However, no genome-wide significant findings have been identified [P≤5e-8], there is limited over-
lap between results from different GWAS, and none of the classical candidate genes for ADHD has been found 
among the top findings. These results may reflect differences in study design or phenotypes analyzed in the differ-
ent GWAS performed so far, and suggest that larger samples, more homogeneous populations and more complex 
statistical strategies are required to identify genetic variants displaying low to moderate effects in ADHD4, 8.
Considering the absence of genome-wide significant associations and the limited overlap between top hits 
from SNP-based GWAS on ADHD, analyses focusing on gene-set enrichment or pathway-based approaches 
raise as promising strategies to address the genetic complexity of the disorder9. These strategies allow combin-
ing effects of multiple SNPs (gene-wide studies) or multiple genes (gene-set analyses), while reducing multiple 
testing comparisons and providing insights into the involvement of specific biological functions or pathways9. In 
this line, Mick et al. performed gene-wide analyses and provided additional evidence for the association between 
ADHD and the solute carrier SLC9A9, a candidate gene for the disorder that had been found nominally asso-
ciated with ADHD in other SNP-based GWAS2–4, 8. Gene-set enrichment approaches or pathway analyses on 
ADHD also highlighted genes involved in the regulation of gene expression, cell adhesion and inflammation, 
ubiquitin-mediated proteasomal degradation, neurodegenerative disorders, axon guidance, neuron projections or 
synaptic components, and revealed significant overlap between pathways enriched for SNP association and those 
enriched for rare copy number variants (CNV)2–4, 8. To integrate findings from GWAS and provide knowledge 
about potential molecular processes underlying ADHD, Poelmans et al. performed network analysis considering 
top findings from five GWAS and revealed that 45 of the 85 top-ranked ADHD candidate genes encoded proteins 
that fitted into a neurodevelopmental network involved in directed neurite outgrowth10. Recently, the Psychiatric 
Genomics Consortium (PGC) combined GWAS signals from over 60,000 subjects to identify common network 
and biological pathways across three adult psychiatric conditions: schizophrenia, major depression and bipolar 
disorder. This study highlighted an important overlap across disorders, with histone methylation processes show-
ing the strongest association, as well as multiple immune and neuronal signaling pathways11.
Due to the lack of robust findings in ADHD through SNP-based GWAS, which may be explained by the lack 
of power of the studies conducted so far and the polygenic, multifactorial nature of the disorder -with common 
and rare variants likely contributing small to moderate effects to its etiology-, we performed gene-wide and path-
way enrichment analyses using GWAS data from 607 persistent ADHD subjects and 584 controls. Subsequently, 
expression profiles of genes surpassing a follow-up significance threshold of P-value < 1e-03 in the gene-wide 
analyses were tested in peripheral blood mononucleated cells (PBMCs) of 45 medication-naive adults with 
ADHD and 39 healthy unrelated controls.
Materials and Methods
Subjects and Clinical Assessment. The clinical sample consisted of 607 adult ADHD subjects and 584 
unrelated healthy individuals, all Spanish and Caucasian. Detailed information regarding the sample is described 
elsewhere12.
The evaluation of the ADHD diagnosis was carried out with the Structured Clinical Interview for DSM-IV 
Axis I and II Disorders (SCID-I and SCID-II) and with the Conners’ Adult ADHD Diagnostic Interview for 
DSM-IV (CAADID parts I and II)13. Severity of ADHD symptoms in adulthood was assessed with the long ver-
sion of the Conners’ ADHD Rating Scale (self-report [CAARS-S:L] and observer [CAARS-O:L])14, the ADHD 
Rating Scale (ADHD-RS)15 and the Wender Utah Rating Scale (WURS) for retrospective symptomatology in 
childhood16. The level of impairment was measured with the Clinical Global Impression (CGI) and the Sheehan 
Disability Inventory17, 18. Additional tests used for clinical assessment are available in Ribasés et al.19. Exclusion 
criteria were IQ < 70; lifelong and current history of mood, psychotic, anxiety, substance abuse, and DSM-IV axis 
II disorders; pervasive developmental disorders; a history or the current presence of a condition or illness, includ-
ing neurologic, metabolic, cardiac, liver, kidney, or respiratory disease; a chronic medication of any kind; birth 
weight ≤ 1.5 kg; and other neurological or systemic disorders that might explain ADHD symptoms.
The control sample consisted of unrelated healthy individuals matched for sex with the clinical group. ADHD 
symptomatology was excluded retrospectively under the following criteria: 1) not having been diagnosed with 
ADHD previously and 2) answering negatively to the life-time presence of the following ADHD symptoms: a) 
often has trouble in keeping attention on tasks; b) usually loses things needed for tasks; c) often fidgets with hands 
or feet or squirms in seat and d) often gets up from seat when remaining in seat is expected.
All subjects were evaluated and recruited at Hospital Universitari Vall d’Hebron of Barcelona (Spain) and 
diagnosis was blind to genotype. The study was approved by the Clinical Research Ethics Committee (CREC) 
of Hospital Universitari Vall d’Hebron, all methods were performed in accordance with the relevant guidelines 
and regulations and written informed consent was obtained from all subjects before the inclusion into the study.
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Gene-wide Analysis. Genome-wide genotyping of 607 adults with ADHD and 584 healthy controls was 
performed with the Illumina HumanOmni1-Quad BeadChip platform [Illumina Inc., San Diego, California, 
USA]. Quality control assessment was implemented at the individual and SNP level using PLINK v1.0720 and 
included filtering subjects with low call rate (<98%) or gender discrepancy, followed by filtering SNPs with minor 
allele frequency (MAF) < 0.01, Hardy-Weinberg equilibrium test P-values (PHWE) < 1e-06 or call rate <0.99 in 
either cases or controls. After stringent quality control assessment, five samples were excluded from the analysis 
due to low call rate and a total of 794,090 SNPs with a mean call rate of 0.9994 for the remaining 603 cases and 583 
controls were included in the study.
Genome-wide association analysis was performed using the Cochran-Armitage trend test with PLINK v1.0720 
and the genomic inflation factor (λ) of 1.031 was used to correct for the degree of inflation12. Gene-wide associa-
tion analyses were conducted with the VEGAS software [VErsatile Gene-Based Association Study; http://gump.
qimr.edu.au/VEGAS/], which combines the effect of all SNPs in a gene locus and corrects for linkage disequilib-
rium (LD)21. Regions were defined using VEGAS default option as ±50 kb upstream and downstream from each 
gene locus (UCSC Genome Browser; NCBI36/hg18 assembly), and the HapMap CEU population was used to 
estimate patterns of LD for each gene. Two different strategies were followed for gene-wide analyses by (i) consid-
ering all SNPs that mapped within a gene locus and (ii) restricting the analysis to the 10% most significant SNPs 
from each gene locus. Multiple-testing adjustment was addressed by the Bonferroni correction, and the signifi-
cance threshold was set at P-value < 1.4e-06, taking into account 17,787 autosomal genes and the two gene-wide 
strategies (0.05/(17,787*2)). Positive signals surpassing a follow-up threshold of P-value < 1e-03 were tested in 
an independent dataset of 2,064 ADHD trios, 896 ADHD cases and 2,455 controls, following the same strategy 
described for the discovery sample7, 22.
Gene-Set and Pathway Analysis. Gene-set and pathway analyses were restricted to genes surpass-
ing a follow-up significance threshold set at P-value < 1e-03 in the gene-wide analyses when either all SNPs or 
the 10% most significant SNPs in gene locus were considered. The definition of the follow-up threshold was 
based on previous evidence supporting that VEGAS software provides an accurate performance for genes with 
P-value < 1e-03, offering a sizeable sensitivity, with less than 1% false positives and specificities ranging from 98% 
to 100%, while being able to distinguish between multiple independent causal loci and multiple signals due to 
linkage disequilibrium23.
The gene-set analyses were performed with MAGMA software [Generalized Gene-Set Analysis of GWAS 
Data; http://ctg.cncr.nl/software/magma]24, a statistical method for analyzing multiple genetic variants simulta-
neously to determine their joint effect while correcting for LD (gene-wide), and subsequently, assembling indi-
vidual genes into groups of genes sharing biological or functional characteristics (gene-set). Multiple-testing 
correction was assessed by 10,000 permutations as implemented in the MAGMA software and the significance 
threshold was set at adjusted P-value < 0.05.
Functional and pathway enrichment analyses were conducted with IPA software [Ingenuity Pathway Analysis; 
Ingenuity Systems®, Redwood City, California, USA; http://www.ingenuity.com]. Fisher’s exact test was used to 
calculate P-values, based on the number of genes/molecules that map to a biological function, disease, pathway, 
or network. A Benjamini-Hochberg’s (BH) threshold of 0.05 was applied for multiple comparison correction in 
the functional, disease and pathway enrichment analyses. Gene networks were considered of relevance when the 
network score (P-score = −log10(P-value)) was over 8 (P-value < 1e-08)25, 26.
Gene expression analysis in peripheral blood mononuclear cells (PBMCs) with microarrays. 
Expression levels of genes identified in the gene-wide study (follow-up P-value threshold <1e-03) were tested in 
PBMCs of 45 medication-naive adults with a new clinical diagnosis of ADHD (69% male; mean age = 38 years 
(SD = 9.9)) and 39 healthy unrelated controls (60% males, mean age = 35 years (SD = 12.1)).
Briefly, PBMCs were isolated using the Ficoll density gradient method, and total RNA was extracted using 
Qiazol Lysis reagent and the RNeasy Midi kit [Qiagen, Hilden, Germany]. The quality of the samples was assayed 
by 2100 Bioanalyzer [Agilent Technologies Inc. Santa Clara, California, USA]. RNA was reverse transcribed 
using the Ambion WT Expression Kit [Life technologies, Massachusetts, USA]. The cRNA was subsequently 
fragmented, labelled and hybridized with the GeneChip WT Terminal Labeling and Hybridization Kit to the 
Genechip Human Gene 1.1 ST 96-Array plate [Affymetrix, Santa Clara, California, USA]. The experiment was 
performed in 9 different amplification rounds, introducing a batch factor that was taken into consideration in 
the following statistical analyses. The array processing and data generation were assessed using the Gene Titan 
Affymetrix microarray platform. Background correction, normalization and summarization of probes values 
was performed using the Robust Multichip Average (RMA) algorithm implemented in the oligo R library27. 
Expression patterns for genes of interest in ADHD subjects and controls were contrasted using the limma R 
library28, including batch and gender as covariates. Bonferroni correction was applied and the significance thresh-
old was set at P-value = 1.5e-03, taking into account the 33 genes displaying P-values below the follow-up thresh-
old in the gene-wide analyses and with microarray data available (0.05/33).
Validation of gene expression differences with reverse transcription real-time quantitative pol-
ymerase chain reaction (RT-qPCR). Validation of gene expression differences was performed on genes 
showing tentative evidence for differential expression in the microarray analysis, which included MAB21L2, 
STXBP3 and RNF122. Gene expression validation assays were conducted with reverse transcription real-time 
quantitative polymerase chain reaction (RT-qPCR) in the same clinical sample of 45 ADHD cases and 39 con-
trols. First, 2 µg of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription 
kit according to manufacturer’s protocol in a final reaction volume of 20 µL [Applied Biosystems; Foster City, 
California, USA]. Following, RT-qPCRs were run in triplicate using 2 µL of cDNA, 2 µL of RNAse free water, 
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5 µL of TaqMan® Gene Expression Master Mix and 1 µL of TaqMan® Gene Expression Assay, in a final reaction 
volume of 10 µL [Applied Biosystems; Foster City, California, USA]. Reactions were measured in an Applied 
Biosystems 7900HT Fast Real-Time PCR system using the default thermal cycling conditions specified by the 
manufacturer [Applied Biosystems; Foster City, California, USA]. The threshold cycle (CT) was defined as the 
fractional cycle number at which the fluorescence exceeded the threshold of 0.2. The relative quantification of 
mRNA expression was calculated by the 2−∆∆CT method29, considering only those samples showing standard 
deviations values ≤ 0.3 among triplicates and the GADD45A gene as an endogenous control, after checking its 
stability and linearity across all samples. Using the Stats R package [https://www.R-project.org/]30, generalized 
linear models (GLM) were applied to compare gene expression levels between ADHD cases and controls, includ-
ing gender as covariate in the fitted model. The statistical test was one-sided and the Bonferroni correction was 
applied for multiple-testing control, setting the statistical significance threshold at P-value < 0.017 when taking 
into account three genes (0.05/3).
Imputation, cis-expression Quantitative Trait Loci (cis-eQTL) Analyses and Prediction of 
Functional Effects. To better delineate the involvement of RNF122 in ADHD and to detect potential func-
tional variants, markers at this locus were imputed in the original dataset of 603 subjects with ADHD and 583 
healthy controls. Pre-imputation quality control of the GWAS dataset at the individual and SNP level was imple-
mented in accordance to the QC module instructions from the Ricopili pipeline considering default settings 
[https://sites.google.com/a/broadinstitute.org/ricopili/]. Screening for cryptic relatedness and population strati-
fication was performed by Principal Components Analysis (PCA). Markers at the RNF122 gene region plus 10 kb 
upstream and 5 kb downstream from the locus (chr8:33519815–33554185; NCBI36/hg18) were imputed in the 
GWAS sample through the pre-phasing and imputation strategies implemented by SHAPEIT and IMPUTE2, 
respectively31, 32, using the Ricopili pipeline [https://sites.google.com/a/broadinstitute.org/ricopili/] and data 
from the 1000 Genomes Project as the reference panel [http://www.1000genomes.org/]33. After filtering SNPs 
with MAF <0.01 and low imputation quality (r < 0.4), 138 SNPs were finally considered. We performed the 
association analysis using logistic regression models with the PLINK v1.07 software20 and multiple-testing was 
addressed by the Bonferroni correction, setting the significance threshold at P-value < 3.6e-04 when consider-
ing 138 imputed SNPs in the RNF122 locus (0.05/138). Since this approach may be too conservative, alterna-
tive multiple-testing control was assessed using the Single Nucleotide Polymorphism Spectral Decomposition 
(SNPSpD) software [http://neurogenetics.qimrberghofer.edu.au/SNPSpDlite/]34, which takes into account pat-
terns of LD (P-value<1.27e-03). Once top signals were identified, in order to uncover additional independent 
effects and to assess evidence for multi-risk loci in each region, further conditioned analysis was performed with 
PLINK v1.07 software20. To condition the logistic regression analysis on a specific SNP, we tested all markers again 
but adding the allelic dosage for the conditioned SNP as a covariate20.
The cis-eQTL analyses were conducted using genotype and expression data from a series of neuropatho-
logically and neuropsychiatrically normal human brain samples from GSE891935 and GSE3027236 datasets, 
available at the Gene Expression Omnibus site [http://www.ncbi.nlm.nih.gov/geo]. Genotype data from both 
studies were imputed following the methodology described above. Expression levels of the RNF122 transcript 
NM_024787.2 were available for 62 cortical samples of European ancestry in the GSE8919 dataset (probe ID: 
GI_38045930-S) and for 94 prefrontal cortex samples of Caucasian origin in the GSE30272 dataset (probe 
ID:HEEBO-062-HCC62D14)35, 36. Rank-based inverse normal transformation of expression data was applied 
using Stats R package [https://www.R-project.org/]30 and additive linear regression models were fitted for eQTL 
mapping using PLINK v1.07 software20, considering covariates showing suggestive association with the outcome 
(P-value < 0.2; gender, age_at_death and transcripts_detected_rate24354 (average transcript detection rate for 
sample, out of all 24354 probes) for GSE8919 and sv2 (surrogate variable 2) for GSE30272 datasets). Bonferroni 
correction was applied for multiple testing and the significance threshold was set at P-value < 4.3e-04 for the 
GSE8919 dataset and at P-value < 3.8e-04 for the GSE30272 dataset, considering the number of available SNPs.
Potential functional effects of the independent risk alleles associated with ADHD were predicted using the 
SNPinfo, ESEfinder, and RESCUE_ESE web softwares37–40.
Results
Gene-Wide and Gene-Set Analysis. After individual and SNP-based standard quality control filtering, 
794,090 autosomal SNPs in 603 adult ADHD cases and 583 healthy controls were included in the GWAS. The 
quantile–quantile plot showed no departure from the expected P-values distribution, with a genomic control 
inflation factor of λ = 1.03112.
The gene-wide association analysis revealed 20 genes surpassing the follow-up significance threshold 
(P-value < 1e-03) when considering all SNPs located within a gene locus, with CTAGE5 (P-value <1.0e-06) 
and FBXO33 (P-value = 3.0e-06) as the most associated genes (Table 1). Twenty additional genes were found 
associated with persistent ADHD when we considered the 10% most significant SNPs of each gene locus, with 
KCNG4 (P-value = 1.0e-04) and TAF1C (P-value = 1.9e-04) as top signals (Table 1). After Bonferroni correction, 
only CTAGE5 remained associated with ADHD. Consistently, the gene-set analysis revealed that both gene-sets 
were significantly associated with persistent ADHD after correcting for multiple comparisons (gene-set cor-
rected P-value = 1e-03 when considering all SNPs within a gene locus and gene-set corrected P-value < 1e-03 
when considering the top 10% SNPs in each locus) (Table 1), although no overlap was detected between them. 
However, some genes highlighted in the previous single-marker GWAS were found among top genes surpassing 
the follow-up significance threshold in the present gene-wide analyses (FBXO33, PEX19, COPA and KCNG4)12.
We further tested the 40 genes surpassing the follow-up threshold of P-value < 1e-03 in an independent data-
set from the first large-scale meta-analysis of ADHD GWAS, consisting of 2,064 ADHD trios, 896 ADHD cases 
and 2,455 controls from the Psychiatric Genetics Consortium7, 22. No signal was associated with ADHD after 
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Chr Gene
Number 
of SNPs
Start 
Position
End 
Position
Gene-wide 
P-value
Loci associated with neuropsychiatric or neurological 
disorders
Full set of SNPs
Global gene-set P-value = 2.2e-4 (Pcorrected = 1.0e-03)
14 CTAGE5 39 38754226 38940148 0*
Antidepressant efficacy in major depressive disorder, 
mild intellectual disability, and traits of inattention and 
hyperactivity61, 66
14 FBXO33 17 38886709 39021371 3.00e-06 Autism spectrum disorders, attention deficit, hyperactivity and mild mental retardation12, 65, 66
14 MIA2 26 38722875 38842326 4.00e-06 Mild intellectual disability, and traits of inattention and hyperactivity61
1 PEX19 10 158463225 158571555 3.40e-05 Major depressive disorder and ADHD12, 67
1 COPA 32 158475000 158629978 4.40e-05 Bipolar Disorder and ADHD12, 68
14 PNN 24 38664137 38772173 6.70e-05 Mild intellectual disability, and traits of inattention and hyperactivity61
1 WDR42A 34 158402128 158548603 8.80e-05 —
1 NCSTN 32 158529686 158645366 1.76e-04 Alzheimer’s Disease and Schizophrenia69, 70
1 MAST2 34 45991871 46324383 3.35e-04 —
1 CASQ1 46 158376988 158488300 3.56e-04 —
15 CALML4 14 66220096 66335502 4.50e-04 Major depressive disorder and stress71, 72
1 ZP4 45 236062332 236170558 5.44e-04 ADHD73, 74
1 IPP 22 45886993 46034720 6.75e-04 Cocaine dependence75
1 TMEM69 19 45876433 45982695 7.12e-04 Amphetamine effects and aggressiveness76, 77
4 MAB21L2 15 151672752 151775295 7.60e-04 Autism spectrum disorders, and mild intellectual disability78–80
1 GPBP1L1 29 45815567 45949398 7.75e-04 Autism spectrum disorders, and traits of inattention in Tourette syndrome81, 82
1 STXBP3 69 109040807 109203671 8.53e-04 —
13 MLNR 16 48642474 48744514 9.24e-04 —
2 NLRC4 26 32253021 32394305 9.36e-04 Schizophrenia, and bipolar disorder83, 84
1 PEA15 37 158391750 158501786 9.42e-04 Major depressive disorder85
Top 10% of SNPs
Global gene-set P-value = 1.12e-10 (Pcorrected < 1.0e-03)
16 KCNG4 118 82763323 82880857 1.00e-04 Alcohol consumption, and bipolar disorder in Amish population86, 87
16 TAF1C 86 82718961 82828163 1.90e-04 Autism and schizophrenia88–90
22 NCF4 48 35536975 35654005 2.10e-04 Schizophrenia91
22 CSF2RB 61 35589620 35716425 3.60e-04 Schizophrenia, major depressive disorder and bipolar disorder92–94
17 AKAP10 18 19699341 19871721 3.80e-04 Autism spectrum disorders, schizophrenia and bipolar disorder95–97
1 ATP1A1 23 116667358 116798919 4.10e-04 Major depressive disorder, autism spectrum disorders, anxiety and bipolar disorder98–101
8 DUSP26 21 33518392 33626981 5.10e-04 Atidepressant Efficacy in Major Depressive Disorder66
12 RAP1B 18 67240918 67390641 5.80e-04 Autism spectrum disorders102, 103
19 AKAP8 9 15275334 15401603 6.10e-04 Autism spectrum disorders95, 104
20 RIN2 113 19768209 19981100 6.40e–04 Bipolar dsorder, schizophrenia and stress-induced changes105–107
2 SPAST 29 32092183 32286210 6.80e-04 Autism spectrum disorders, and cognitive deficiency109, 110
7 CCL26 34 75186777 75307000 7.10e-04 Schizophrenia, and bipolar disorder111, 112
20 NAT5 59 19895936 20012269 7.60e-04 Autism spectrum disorders and comorbid anxiety113
8 RNF122 31 33474814 33594185 7.70e-04 Antidepressant efficacy in major depressive disorder66
15 C15orf53 66 36726090 36829531 7.90e-04 Bipolar disorder, and alcohol dependence108, 114
7 GPR146 34 1013666 1115423 8.90e-04 Autism spectrum disorders115, 116
8 C8orf41 25 33425777 33540245 9.20e-04 Antidepressant efficacy in major depressive disorder, and cognitive deficiency66, 117, 118
2 MEMO1 25 31896397 32139202 9.20e-04 —
12 ALX1 16 84148166 84269692 9.30e-04 Autism spectrum disorders119, 120
7 GPER1 36 1042968 1149977 9.40e-04 Anxiety and stress, bipolar disorder, and antipsychotic treatment for schizophrenia121–124
Table 1. Gene-wide and gene-set P-values considering all SNPs or the 10% most significant SNPs in gene locus 
using VEGAS and MAGMA softwares. Genes displaying P-value < 1e-03 are shown. Start and end positions 
include default flanking regions of ±50 Kb from 5′ and 3′ UTRs of each gene, defined by default by VEGAS 
software (http://gump.qimr.edu.au/VEGAS/), and are based on UCSC annotation, build NCBI36/hg18 (Mar. 
2006). *An empirical P-value of 0 (from 106 simulations) can be interpreted as P-value < 106, which exceeds a 
Bonferroni-corrected threshold set at P-value < 2.8e-06 (~0.05/17,787).
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 5407  | DOI:10.1038/s41598-017-05514-7
Bonferroni correction. Nominal signals, however, were found for FBXO33 (P-value = 0.047 when considering all 
SNPs in the gene locus and P-value = 0.01 when considering the top 10% SNPs) and C15orf53 (P-value = 0.036 
when considering the top 10% SNPs in the gene locus) (see Supplementary Table S1).
Functional and Pathway Analysis. Although none of them survived BH multiple-testing correction, 
enrichment for eight canonical pathways was detected when the 40 genes from the two gene-sets identified in the 
gene-wide association analysis were considered jointly, including protein kinase A (PKA) and cAMP-mediated 
signaling (P-value = 5.75e-03 and P-value = 7.94e-03, respectively), serine biosynthesis and superpathway of 
serine and glycine biosynthesis (P-value = 9.33e-03 and P-value = 1.29e-02, respectively), assembly of RNA 
polymerase I complex (P-value = 1.66e-02), cardiac adrenergic signaling (P-value = 2.57e-02), inflammas-
ome pathway (P-value = 3.80e-02) and calcium signaling (P-value = 4.27e-02) (Fig. 1). Among the top func-
tions and diseases, most enriched categories were mainly related to organismal and embryonic development 
(P-value = 2.58e-04–4.00e-02), cell-to-cell signaling and interaction (P-value = 3.96e-04–3.47e-02) and cellular 
movement (P-value = 1.28e-03–3.60e-02) (Table 2). In addition, several nervous system-related terms and psy-
chological traits were also identified among enriched categories, such as relaxation of mice (P-value = 5.55e-03), 
swelling of neurites (P-value = 7.40e-03), axonal transport of vesicles (P-value = 9.24e-03), abnormal morphology 
of nervous system (P-value = 1.10e-02) or addiction behaviour (P-value = 4.36e-02) (Table 3). Three relevant 
networks that included genes mainly related to cellular development, organization, function and maintenance, 
cell death and survival, and cell-to-cell signaling and interaction were generated (Table 4). The two most relevant 
Figure 1. Enriched canonical pathways (P-value < 0.05) considering 40 genes from the gene-wide analyses 
surpassing follow-up significance threshold (P-value < 1e-03). The −log(P-value) from the Fisher’s exact test for 
each enriched category is indicated by grey bars. The ratio indicates the number of genes tested that map to the 
canonical pathway divided by the total number of genes that map to that pathway, and is represented by dark 
grey squares.
Super-category P-value Molecules
Embryonic Development 2.58e-04–3.83e-02 NCSTN, ALX1, CSF2RB, PNN, MAB21L2, PEA15
Organismal Development 2.58e-04–4e-02 NCSTN, GPER1, ALX1, COPA, ATP1A1, CSF2RB, AKAP8, RAP1B, MAB21L2, NLRC4, PEA15
Tissue Development 2.58e-04–4.94e-02 NCSTN, GPER1, ALX1, CSF2RB, RAP1B, IPP, MAB21L2
Cell-To-Cell Signaling and Interaction 3.96e-04–3.47e-02 NCF4, CCL26, CSF2RB, STXBP3, RAP1B
Cellular Movement 1.28e-03–3.65e-02 NCF4, CCL26, GPER1, CSF2RB, RAP1B, NLRC4
Hematological System Development and Function 1.28e-03–4.89e-02 CCL26, NCF4, NCSTN, CSF2RB, RAP1B, NLRC4
Immune Cell Trafficking 1.28e-03–3.65e-02 NCF4, CCL26, CSF2RB, RAP1B, NLRC4
DNA Replication, Recombination, and Repair 1.51e-03–2.39e-02 GPER1, AKAP8, PEA15
Cardiovascular System Development and Function 1.85e-03–2.39e-02 AKAP10, GPER1, ATP1A1, CSF2RB, RAP1B
Cell Cycle 1.85e-03–3.65e-02 PEX19, PNN, NLRC4, PEA15
Table 2. Top-ten enriched super-categories from disease and functional enrichment analyses using IPA 
software, considering 40 genes identified in the gene-wide analyses surpassing follow-up significance threshold 
(P-value < 1e-03).
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networks were highly scored (P-score = 44 and P-score = 26, respectively) and included 18 (45%) and 12 (30%) 
out of the 40 genes considered for this analysis.
Gene expression analysis in peripheral blood mononuclear cells (PBMCs). Expression levels of 
the 40 genes in the two gene-sets identified in the gene-wide association study were explored in microarray data 
from peripheral blood mononuclear cells (PBMCs) of 45 adults with ADHD and 39 healthy controls. No data 
were available for two of them (WDR42A and NAT5) and another five were excluded because the corresponding 
probes matched to multiple genes (COPA, TMEM69, TAF1C, MEMO1, C8orf41). Although no significant expres-
sion differences were identified after Bonferroni correction, tentative evidence for overexpression was detected 
in ADHD subjects for STXBP3 (P-value = 1.9e-03; log fold change = 0.115) and RNF122 (P-value = 0.045; log 
fold change = 0.111) and decreased expression for MAB21L2 (P-value = 0.036; log fold change = −0.77) when 
Super-Categories Diseases or Functions Categories P-value Molecules
Hereditary Disorder, Neurological Disease, Organismal Injury 
and Abnormalities
autosomal dominant spastic 
paraplegia type 4 1.85e-03 SPAST
Developmental Disorder, Hereditary Disorder, Neurological 
Disease, Organismal Injury and Abnormalities
autosomal recessive mental 
retardation type 39 1.85e-03 TTI2
Developmental Disorder, Neurological Disease, Organismal 
Injury and Abnormalities meroanencephaly 1.85e-03 ALX1
Organismal Development relaxation of mice 5.55e-03 ATP1A1
Connective Tissue Disorders, Developmental Disorder, 
Neurological Disease, Skeletal and Muscular Disorders acrania 7.40e-03 ALX1
Cell Morphology, Cellular Assembly and Organization, 
Cellular Development, Cellular Function and Maintenance, 
Cellular Growth and Proliferation, Neurological Disease, 
Organismal Injury and Abnormalities
swelling of neurites 7.40e-03 SPAST
Nervous System Development and Function antinociception of spinal cord 9.24e-03 GPER1
Cellular Assembly and Organization, Cellular Function and 
Maintenance, Nervous System Development and Function axonal transport of vesicles 9.24e-03 SPAST
Nervous System Development and Function abnormal morphology of nervous system 1.10e-02
ALX1, MAB21L2, 
PEA15, RAP1B, SPAST, 
STXBP3
Connective Tissue Disorders, Developmental Disorder, 
Organismal Development, Skeletal and Muscular Disorders clefting of face 1.29e-02 ALX1
Embryonic Development, Nervous System Development and 
Function, Organismal Development, Tissue Morphology abnormal morphology of neural crest 1.47e-02 NCSTN
Cell Morphology, Nervous System Development and 
Function, Tissue Morphology abnormal morphology of neurites 3.92e-02 RAP1B, SPAST
Connective Tissue Development and Function, Organ 
Morphology, Organismal Development, Skeletal and Muscular 
System Development and Function, Tissue Development
abnormal morphology of 
supraoccipital bone 4.00e-02 ALX1
Behavior addiction behaviour 4.36e-02 ATP1A1
Cell Morphology, Nervous System Development and 
Function, Neurological Disease, Tissue Morphology loss of axons 4.89e-02 RAP1B
Table 3. Significant nervous system-related categories identified in the disease and functional enrichment 
analyses using IPA software, considering 40 genes identified in the gene-wide analyses surpassing follow-up 
significance threshold (P-value < 1e-03).
Molecules in Network P-score*
Focus 
Molecules Top Diseases and Functions
ABL1, AKAP8, AKAP10, Akt, ATP1A1, C1QBP, caspase, CASQ1, 
CCL26, COPA, CSF2RB, DDX3X, EMILIN1, ERK, ERK1/2, Gpcr, 
GPER1, GPR146, Insulin, MAST2, MEMO1, MLNR, NCF4, 
NCSTN, NFkB (complex), NLRC4, P38 MAPK, PEA15, PI3K 
(complex), Pka, Pkc(s), RAP1B, STXBP3, TARDBP, TRAF6
44 18
Cell-To-Cell Signaling and Interaction, 
Cellular Development, Hematological 
System Development and Function
AES, APP, C3orf33, CEP57, Collagen type VII, CTAGE5, DCAF8, 
DGCR6/LOC102724770, DUSP26, ELAVL1, EMILIN1, FAM20B, 
FBXO33, GPBP1L1, HIGD2A, HINT3, HSP90AB1, MAB21L2, 
MAPK3, MMP3, PEX19, PEX26, PLD6, PNN, RAF1, RBX1, 
RIN2, RNF122, SELT, SPAST, TARDBP, TMTC4, TRAF6, TTI2, 
YBX1
26 12
Cellular Assembly and Organization, 
Cellular Compromise, Cellular Function 
and Maintenance
ABL1, Actin, ALB, ALX1, BZW2, CALML4, Cdc2, CDC25A, 
CREB1, CUL1, CYBA, Cyclin B, EGLN1, EPO, GABBR1, GDF15, 
HNF1A, IKBKB, IPP, IRF3, KHDRBS1, KRT8, KRT18, LANCL1, 
MIA2, mir-296, MYB, MYBL2, MYO5B, NAA20, TAF1C, 
TARDBP, TGFB1, TRAF6, YBX1
11 6
Cell Death and Survival, Digestive System 
Development and Function, Hepatic System 
Development and Function
Table 4. Significant generated networks (P-score < 8) using IPA software, considering 40 genes identified in the 
gene-wide analyses surpassing follow-up significance threshold (P-value < 1e-03). Focus molecules from the 
follow-up gene-set are shown in bold. *P-score = −log10(P-value).
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compared to controls (Table 5). Differences in RNF122, STXBP3 and MAB21L2 expression levels were subse-
quently tested by RT-qPCR and evidence for significant overexpression was confirmed for RNF122 (but not for 
STXBP3 or MAB21L2) after controlling for multiple testing using the Bonferroni correction (P-value = 3.04e-03; 
OR = 4.13 [2.46–5.81]); Table 6).
Cis-expression Quantitative Trait Loci (cis-eQTL) Analyses and Prediction of Functional 
Effects. To better define the role of RNF122 in ADHD and to detect potential functional variants, we imputed 
markers at this locus in the original dataset of 603 subjects with ADHD and 583 healthy controls and found 
47 out of 138 SNPs nominally associated with ADHD. Although none of them exceeded the conservative 
Bonferroni-corrected threshold, three surpassed the SNPSpD multiple-testing correction (rs3735951, rs9297208 
and rs9297209) (See Supplementary Figure S1). Suggestive evidence for association was detected along the 
entire gene, with the top signal at the genotyped variant rs3735951, located in exon 2, being the allele T the 
risk one (P-value = 8.18e-04; OR = 1.37[1.14–1.65]) (See Supplementary Figure S1). After conditional analysis, 
no evidence for additional independent effects was detected along the gene, being the entire association of this 
locus explained by the rs3735951 marker (See Supplementary Table S2). Although we did not find evidence for 
rs3735951 acting as cis-eQTL in preexisting datasets of cortical gene expression (GSE8919 and GSE30272)35, 36, 
that could explain the RNF122 expression differences identified in ADHD (See Supplementary Table S3), func-
tional prediction revealed that rs3735951 may lie within a partially overlapped exonic splicing enhancer (ESE) 
site and an exonic splicing silencer (ESS) site (See Supplementary Table S4). While the rs3735951T risk allele may 
create an ESE site potentially targeted by the spliceosome factors SRSF2 and SRSF5, the rs3735951C allele may 
generate an ESS site (See Supplementary Table S4).
Discussion
With the aim of uncovering new underlying genes involved in persistent ADHD and providing additional evi-
dence for the contribution of previously identified genes, we performed gene-wide and pathway enrichment anal-
yses in a pre-existing GWAS dataset of adult ADHD followed by gene expression profiling. Our results provide 
Probe 
ID
Log-Fold 
change P-value
Gene 
Symbol Description
8150186 0.111 0.048 RNF122
Localizes to the endoplasmic reticulum and golgi apparatus and may be associated 
with cell viability by inducing necrosis and apoptosis. Mediates protein-protein and 
protein-DNA interactions, and has been identified as a new E3 ubiquitin ligase that 
can ubiquitinate itself and undergo degradation in a RING finger-and proteasome-
dependent manner41.
7903541 0.115 2.3e-03 STXBP3 Plays an integral role in vesicle transport through their interaction with SNAREs and could play a positive regulatory role in SNARE assembly125.
8097773 -0.77 0.034 MAB21L2 Required for several aspects of embryonic development including normal development of the eye. May be involved in neural development80.
Table 5. Differentially expressed genes in peripheral blood mononucleated cells (PBMCs) of 45 
pharmacologically-naive ADHD subjects and 39 healthy unrelated controls in the microarray analysis.
Gene name Gene Symbol Gene ID Location Assay ID
Amplicon 
Size
Assay information of target and control genes
Housekeeping gene
growth arrest and 
DNA damage 
inducible alpha
GADD45A 1647 1p31.2 Hs00169255_m1 123
Target genes
mab-21-like 2 MAB21L2 10586 4q31 Hs00740710_s1 93
syntaxin binding 
protein 3 STXBP3 6814 1p13.3 HS01029364_m1 149
ring finger protein 
122 RNF122 79845 8p12 Hs00227141 99
Target gene Control gene ODDS Ratio Standard Error Z-value P-value Number of controls
Number of 
cases
Results from RT-qPCR validation of MAB21L2, STXBP3 and RNF122 genes
RNF122 GADD45A 4.133 0.517 2.744 3.04e-03 34 42
STXBP3 GADD45A 2.361 0.521 1.648 0.049 40 44
MAB21L2 GADD45A 0.866 0.701 −0.206 0.419 35 25
Table 6. Validation of MAB21L2, STXBP3 and RNF122 gene expression differences between 
pharmacologically-naive ADHD subjects and healthy unrelated controls by RT-qPCR. Statistically significant 
P-values after applying a Bonferroni threshold of P-value < 0.017, when taking into account three genes 
(0.05/3), are shown in bold.
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preliminary evidence for genetic association between ADHD and the RNF122 gene and abnormal RNF122 
expression levels in PBMCs of medication-naive ADHD subjects. These findings highlight RNF122 as a strong 
candidate for ADHD.
RNF122 (RING Finger Protein 122) is an E3 ubiquitin ligase involved in the proteasome-mediated processing, 
trafficking, and degradation of proteins that acts as an essential mediator of the substrate specificity of ubiqui-
tin ligation41. This finding is in line with previous genome-wide analyses supporting the involvement of genes 
related to the ubiquitination machinery in the genetic susceptibility to ADHD or attention function, including 
the FBXO33 and PARK2 genes, which also encode components of the E3 ubiquitin-protein ligase complex12, 42. 
Interestingly, the second most significant network identified in the present study revealed an indirect connection 
between RNF122 and FBXO33, and included other best hits such as MAB21L2 or PEX19 (Tables 1 and 3). The 
ubiquitin-proteasome pathway controls wide-ranging functions in the central nervous system (CNS), including 
fine-tuning of synaptic connections during development and synaptic plasticity in the adult organism, and has 
been identified as a well-founded pathway for other psychiatric or neurological conditions, including bipolar 
disorder, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, intellectual disability or 
autism spectrum disorder43–50. In line with these findings, the identification of “Protein Kinase A Signaling” and 
“cAMP-mediated Signaling” as the two most significantly enriched canonical pathways may also support the role 
of the identified genes in adult synaptic plasticity mediated by the ubiquitin-proteasome system since ubiquit-
ination, degradation and subsequent removal of regulatory subunits of protein Kinase A in response to cAMP 
stimulation induce neuronal differentiation and activity, as well as synaptic plasticity (Fig. 1)43, 44, 52, 53.
The overexpression of RNF122 that we found in persistent ADHD is in agreement with previous studies 
reporting increased expression levels of E3 ubiquitin ligases in neuropsychiatric disorders51, 54. Given its role in 
synaptic surface-protein turnover and in the regulation of the number of scaffolding proteins and neurotrans-
mitter receptors, increased ubiquitin ligation and subsequent enhanced protein removal may compromise neu-
ronal functioning43, 55, 56. Although its consequences in the remodelling of the synaptic density should be further 
investigated, enhanced ubiquitin-proteasome pathway activity may entail downregulation of synaptic receptors, 
such as gamma-aminobutyric acid (GABA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), 
N-methyl-d-aspartate (NMDA) or nicotinic acetylcholine (nACh) receptors; and eventually lead to the neuro-
pathological mechanisms that likely underlie neuropsychiatric disorders51, 54, 56–60.
We also identified a significant association between CTAGE5 and persistent ADHD after Bonferroni cor-
rection. CTAGE5, together with other top hits identified in the gene-wide analyses, namely FBXO33, MIA2 and 
PNN, lies within a genomic segment on chromosome 14 that was found to be deleted in three subjects with 
different neurologic and/or psychiatric traits, such as mild mental retardation, severe learning difficulties, motor 
alterations or ADHD symptoms61. FBXO33 gene encodes a member of the F-box protein family which acts as 
a component of an E3 ubiquitin-protein ligase complex and is involved in targeting substrates for proteasomal 
degradation, while CTAGE5 and MIA2 genes are both involved in the traffic of large cargos from the endoplasmic 
reticulum to the Golgi apparatus, a process that involves ubiquitination62. Thus, together with the involvement of 
RNF122 in ADHD, these findings highlight the need for further studies exploring in depth the potential role of 
the ubiquitin - proteasome pathway in the susceptibility to ADHD.
Additionally, nominal signals were identified for C15orf53 and FBXO33 in both the discovery and the 
replication datasets. Interestingly, C15orf53 has previously been associated with bipolar disorder and alcohol 
dependence, and FBXO33, which may be involved in autism spectrum disorders, was highlighted in the previous 
SNP-based GWAS that we performed in the same discovery dataset and provides additional evidence supporting 
the ubiquitination machinery as a new mechanism for ADHD7, 22.
Our study should be viewed in light of several methodological considerations:
First, we attempted to overcome SNP-based GWAS limitations by using a gene-wide approach, a promising 
complement to GWAS since it considers the combined effects of all genetic variants within a locus and might be 
more powerful than traditional SNP-based strategies9. Our modest sample size and the anticipated small effect of 
common polymorphisms in complex traits, however, may have prevented us from detecting additional signals, 
apart from CTAGE5, exceeding the conservative Bonferroni correction. Additionally, although controls were 
screened retrospectively for ADHD symptoms, no specific scale or structured interview was used to discard the 
presence of other psychiatric disorders and, therefore, certain degree of heterogeneity in the control sample may 
exist and might influence our results.
Second, the conditional analysis highlighted rs3735951 as the top-ranked variant at the RNF122 locus and 
eliminated evidence for association for other SNPs within the region. This sequence variant did not tag any eQTL 
for RNF122 in human brain samples from two available pre-existing data sets35, 36, but lies within potential exonic 
splicing regulatory elements. Specifically, the rs3735951T risk allele is predicted to create an exonic splicing 
enhancer (ESE), potentially targeted by SRSF2 and SRSF5 spliceosome factors, which could result in alternative 
splicing of the RNF122 transcript and, thus, modulate substrate specificity or ligation function (Supplementary 
Table S4)37–40. Given that rs3735951 lies within a LD block that spans the entire gene, however, we cannot discard 
additional relevant variants within the locus exerting functional effects.
Third, while we identified genes displaying biologically interesting functions and pathways pointing to the 
ubiquitin-proteasome pathway as a promising candidate system, no overlap was observed between our gene-wide 
results and previous findings in ADHD through either individual GWAS or meta-analysis2–4, 8. The replication 
attempt in an independent sample, however, yielded preliminary evidence for nominal association of ADHD with 
FBXO33 and C15orf53. Heterogeneity between populations and differences in study design or in the proportion 
of persistent ADHD between datasets may account for discordant results across studies, making it difficult to 
establish direct comparisons between reports. For this reason, further replication of the gene-wide and gene 
expression results in independent cohorts are needed to confirm these associations and to estimate the magnitude 
of their effects.
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Fourth, aberrant RNF122 expression levels were detected in PBMCs of ADHD subjects, naive for pharmaco-
logical treatment. Transcriptome analysis in peripheral blood has become an increasingly useful tool in the search 
for biomarkers in multiple medical fields, including psychiatric disorders, given their great deal of potential for 
non-invasive screening, diagnosis and prognosis, or for differentiation of biological endophenotypes, develop-
ment of targeted therapies and anticipation of clinical response or adverse effects63. Although whole blood shares 
substantial transcriptome similarities with different CNS tissues so as to use peripheral expression profiles as a 
surrogate for gene expression in the CNS, further evidence in brain tissues is required to assert the role of RNF122 
in the pathophysiology of ADHD64.
In conclusion, we performed gene-wide and pathway enrichment analyses using data from a pre-existing 
GWAS dataset of persistent ADHD and provided tentative evidence for the involvement of the CTAGE5 and 
RNF122 genes in the susceptibility to the disorder. We also detected overexpression of the RNF122 gene in 
PBMCs of adult ADHD patients, placing this gene as a promising candidate for the disorder. The evidence pro-
vided by our findings point to the ubiquitin-proteasome system as a well-founded pathway involved in the etiol-
ogy of ADHD. Further collaborative efforts are required to disentangle the exact molecular mechanisms by which 
CTAGE5, RNF122, and the ubiquitin-proteasome system may contribute to the pathophysiology of ADHD and 
other neuropsychiatric disorders.
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